A platform for research: civil engineering, architecture and urbanism
A platform for research: civil engineering, architecture and urbanism
A Novel Blood‐Based Colorectal Cancer Diagnostic Technology Using Electrical Detection of Colon Cancer Secreted Protein‐2
Colorectal cancer (CRC) is the second‐leading cause of cancer‐related mortality worldwide, which may be effectively reduced by early screening. Colon cancer secreted protein‐2 (CCSP‐2) is a promising blood marker for CRC. An electric‐field effect colorectal sensor (E‐FECS), an ion‐sensitive field‐effect transistor under dual gate operation with nanostructure is developed, to quantify CCSP‐2 directly from patient blood samples. The sensing performance of the E‐FECS is verified in 7 controls and 7 CRC samples, and it is clinically validated on 30 controls, 30 advanced adenomas, and 81 CRC cases. The concentration of CCSP‐2 is significantly higher in plasma samples from CRC and advanced adenoma compared with controls (both P < 0.001). Sensitivity and specificity for CRC versus controls are 44.4% and 86.7%, respectively (AUC of 0.67), and 43.3% and 86.7%, respectively, for advanced adenomas (AUC of 0.67). CCSP‐2 detects a greater number of CRC cases than carcinoembryonic antigen does (45.6% vs 24.1%), and the combination of the two markers detects an even greater number of cases (53.2%). The E‐FECS system successfully detects CCSP‐2 in a wide range of samples including early stage cancers and advanced adenoma. CCSP‐2 has potential for use as a blood‐based biomarker for CRC.
A Novel Blood‐Based Colorectal Cancer Diagnostic Technology Using Electrical Detection of Colon Cancer Secreted Protein‐2
Colorectal cancer (CRC) is the second‐leading cause of cancer‐related mortality worldwide, which may be effectively reduced by early screening. Colon cancer secreted protein‐2 (CCSP‐2) is a promising blood marker for CRC. An electric‐field effect colorectal sensor (E‐FECS), an ion‐sensitive field‐effect transistor under dual gate operation with nanostructure is developed, to quantify CCSP‐2 directly from patient blood samples. The sensing performance of the E‐FECS is verified in 7 controls and 7 CRC samples, and it is clinically validated on 30 controls, 30 advanced adenomas, and 81 CRC cases. The concentration of CCSP‐2 is significantly higher in plasma samples from CRC and advanced adenoma compared with controls (both P < 0.001). Sensitivity and specificity for CRC versus controls are 44.4% and 86.7%, respectively (AUC of 0.67), and 43.3% and 86.7%, respectively, for advanced adenomas (AUC of 0.67). CCSP‐2 detects a greater number of CRC cases than carcinoembryonic antigen does (45.6% vs 24.1%), and the combination of the two markers detects an even greater number of cases (53.2%). The E‐FECS system successfully detects CCSP‐2 in a wide range of samples including early stage cancers and advanced adenoma. CCSP‐2 has potential for use as a blood‐based biomarker for CRC.
A Novel Blood‐Based Colorectal Cancer Diagnostic Technology Using Electrical Detection of Colon Cancer Secreted Protein‐2
Jeun, Minhong (author) / Lee, Hyo Jeong (author) / Park, Sungwook (author) / Do, Eun‐ju (author) / Choi, Jaewon (author) / Sung, You‐Na (author) / Hong, Seung‐Mo (author) / Kim, Sang‐Yeob (author) / Kim, Dong‐Hee (author) / Kang, Ja Young (author)
Advanced Science ; 6
2019-06-01
10 pages
Article (Journal)
Electronic Resource
English
COLON CANCER: EARLY DETECTION IS KEY
| British Library Online Contents | 2011
Strategies for Colon Cancer Prevention
| Wiley | 1995
Exposure to widespread drinking water chemicals, blood inflammation markers, and colorectal cancer
| DOAJ | 2021
Molecular Genetics of Colorectal Cancer
| Wiley | 1995